Teriparatide Biosimilar – Anti-PTH – Research Grade from ProteoGenix; catalogue PX-TA2297; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Teriparatide Biosimilar, also known as Anti-PTH, is a research grade antibody that has been developed to target the parathyroid hormone (PTH) and its receptor. This biosimilar is a promising therapeutic option for the treatment of osteoporosis, a condition characterized by low bone mass and increased risk of fractures. In this article, we will provide a detailed description of the structure, activity and potential applications of Teriparatide Biosimilar.
Teriparatide Biosimilar is a monoclonal antibody that is produced through recombinant DNA technology. It is a fully humanized antibody, meaning that it is derived from human cells and has a high affinity for its target. The antibody has a molecular weight of approximately 150 kDa and is composed of two identical heavy chains and two identical light chains. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains have two constant domains (CL) and one variable domain (VL). The variable domains of the antibody are responsible for binding to the PTH receptor and initiating its biological activity.
Teriparatide Biosimilar works by binding to the PTH receptor, which is located on the surface of bone cells called osteoblasts. This binding activates a signaling pathway that leads to an increase in the production of new bone tissue and a decrease in bone resorption. This results in an overall increase in bone density and strength, making it an effective treatment for osteoporosis. Additionally, Teriparatide Biosimilar has been shown to stimulate the production of osteoblasts and inhibit the formation of osteoclasts, further promoting bone growth and maintenance.
The therapeutic target of Teriparatide Biosimilar is the PTH receptor, which is a G-protein coupled receptor (GPCR) that is expressed on the surface of osteoblasts. The PTH receptor is activated by the parathyroid hormone, which is responsible for regulating calcium and phosphate levels in the body. In individuals with osteoporosis, the PTH receptor is overactive, leading to increased bone resorption and decreased bone formation. By targeting the PTH receptor, Teriparatide Biosimilar can restore the balance between bone resorption and formation, ultimately improving bone health.
Teriparatide Biosimilar has been primarily developed for the treatment of osteoporosis. It has been shown to significantly increase bone mineral density and reduce the risk of fractures in individuals with the condition. Additionally, Teriparatide Biosimilar has been investigated for its potential use in other bone-related disorders, such as osteogenesis imperfecta and bone metastases. It has also shown promising results in preclinical studies for the treatment of rheumatoid arthritis and bone loss associated with aging.
In summary, Teriparatide Biosimilar is a research grade antibody that specifically targets the PTH receptor and has shown promising results for the treatment of osteoporosis. Its unique structure and mechanism of action make it a potential therapeutic option for other bone-related disorders as well. Further research and clinical trials are needed to fully understand the potential of this biosimilar in the field of bone health.
ProteoGenix catalogue number PX-TA2297. For research use only.
Target: PTH; Host: Human; Clonality: Polyclonal Antibody.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
